long intergenic non-protein coding RNA 1645Genealiases: []
Q-omics provides the consensus-scored LINC01645 profile across patient tissues and cancer cell-line models. LINC01645 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, LINC01645 is differentially expressed in 9, with the highest sampling consensus in COAD. Additionally, LINC01645 RNA expression shows 13,231 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight STAD, COAD, and UVM as cancer lineages where LINC01645 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01645 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01645 survival associations across molecular data types. LINC01645 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01645 RNA expression–survival associations across cancer types. High LINC01645 expression shows unfavorable associations in STAD, PRAD and DLBC, but favorable associations in LGG, BRCA and CHOL. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify STAD as the clearest survival context for LINC01645 RNA expression.
This table summarizes LINC01645 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01645. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01645 shows lower tumor expression in COAD, LUSC, LUAD, BRCA and KICH and higher tumor expression in THCA. The COAD box plot shows higher LINC01645 RNA expression in normal versus tumor tissue (log2 FC = −2.674, t-test p < 0.001).
This table shows molecular features associated with LINC01645 in patient tissues and cancer cell lines. In patient samples, LINC01645 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
